Pulmonary hypertension (PH) is a serious disease of multiple etiologies mediated by hypoxia, immune stimuli, and elevated pulmonary pressure that leads to vascular thickening and eventual right heart failure. In a chronic hypoxia model of PH, we previously reported the induction of a novel pleiotropic cytokine, hypoxia-induced mitogenic factor (HIMF), that exhibits mitogenic, vasculogenic, contractile, and chemokine properties during PH-associated vascular remodeling. To examine the role of HIMF in hypoxia-induced vascular remodeling, we performed in vivo knockdown of HIMF using shRNA directed at rat HIMF in the chronic hypoxia model of PH. Knockdown of HIMF partially blocked increases in mean pulmonary artery pressure, pulmonary vascular resistance, right heart hypertrophy and vascular remodeling caused by chronic hypoxia. To demonstrate a direct role for HIMF in the mechanism of PH development, we performed HIMF-gene transfer into the lungs of rats using a HIMF-expressing adeno-associated virus (AAV). AAV-HIMF alone caused development of PH similar to that of chronic hypoxia with increased mean pulmonary artery pressure and pulmonary vascular resistance, right heart hypertrophy, and neomuscularization and thickening of small pulmonary arterioles. The findings suggest that HIMF represents a critical cytokine-like growth factor in the development of PH.
INTRODUCTION
Pulmonary hypertension (PH) is a complex disease with multiple etiologies, including hypoxia, immune stimuli, and elevated pulmonary pressure. It can occur as pulmonary arterial hypertension, without a specific cause, or more commonly, secondary to other disease processes (12, 29) . Pulmonary inflammation has been increasingly associated with many forms of PH. Despite the complexity of this disease, both clinical and experimental studies reveal common pathological features, the most important of which is pulmonary vascular remodeling (13, 37) . This process involves endothelial dysfunction and proliferation as well as smooth muscle cell proliferation. Proliferation of these cell types thickens pulmonary vessels and narrows the lumen, particularly of small resistance vessels, resulting in increased pulmonary vascular resistance (PVR). Over time, this increased resistance leads to progressive right ventricular (RV) hypertrophy ending with right heart failure and death (12, 28) . Currently, the mechanism(s) of pulmonary vascular remodeling in PH is poorly understood and therapy remains inadequate.
We previously identified a novel gene product that is upregulated in the remodeling lung vasculature in a murine model of hypoxia-induced PH (34) . This molecule, which we named growth following pneumonectomy (16). The HIMF expression pattern in these models was consistent with those of our previous study (34) . In vivo, the addition of recombinant HIMF protein directly into the lung increases PCNA staining of several types of pulmonary cells (16) and recruitment of CD68-and CD34-positive-staining cells (41). HIMF is known to be induced by hypoxia and by activation of Th2-related immune pathways (IL-4 and IL-13); both stimuli have been implicated in the etiology of many forms of human PH and in animal models (6, 7, 12, 32, 34) . All of these data suggest a role for HIMF in the vascular remodeling and hemodynamic changes of PH, but until now actual proof of a role for HIMF in the pathophysiology of PH has been lacking.
In this study, we tested the hypothesis that HIMF could induce the vascular and hemodynamic changes similar to those stimulated by PH and that blockade of HIMF could ameliorate the vascular remodeling and hemodynamic changes associated with the classical chronic hypoxia-induced rodent model of PH. We found that in vivo knockdown of HIMF in the chronic hypoxia model of PH partially blocked the vascular remodeling and hemodynamic changes of PH, including increased mean pulmonary artery pressure (mPAP) and PVR, thickening and muscularization of small arterioles, and RV hypertrophy. Also, in vivo pulmonary gene transfer of HIMF increased these same markers. This evidence implicates HIMF as a novel hypoxia-and Th2-activated pleiotropic cytokine in the pulmonary vascular remodeling and hemodynamic changes of PH.
MATERIALS AND METHODS

Experimental animals. Adult male Sprague-Dawley rats weighing 200-250 g (Hilltop Lab
Animals; Scottsdale, PA) were used for all experiments. Animal housing and experimental protocols were approved by the Animal Care and Use Committee of the Johns Hopkins University.
HIMF/FIZZ1/RELMα in Pulmonary Hypertension 6 Viral vectors. To induce controlled expression of HIMF in the intact rat lung, we used a recombinant adeno-associated virus (AAV) vector that selectively expresses murine HIMF. This AAV vector was designed with the ubiquitous CB promoter. It was prepared by the vector core lab located at the University of Florida (Dr. Terry Flotte). We used a similar empty AAV vector (AAV-null) to control for the possibility of viral-associated effects. To achieve suppression of HIMF in the intact rat lung, we used a recombinant, replication-defective adenovirus (Ad) that expresses green fluorescent protein (GFP) and an artificial miRNA engineered to selectively suppress HIMF expression (Ad-EmGFP-HIMF-shRNAmiR). Construction of the artificial miRNA was based on an endogenous murine miRNA (miR-155) (14) whose short hairpin (sh) RNA sequence was replaced by shRNA sequences targeting HIMF. This was then incorporated into a commercial vector in the GATEWAY recombination cloning system (pcDNA6.2-DEST, Invitrogen Corp, Carlsbad, CA). In this vector, the shRNA containing the antisense to the target sequence in rat HIMF (NM_053333) was placed downstream of a cDNA encoding a modified GFP (EmGFP) so that it was transcribed along with the EmGFP. The target sequence for rat HIMF (5'-gataactatccctctgctgca-3'; bp 156-176) used in this study was chosen from among four different sequences generated by web-based selection programs in a screen in which individual shRNAmiRs were co-transfected into HEK293 cells along with a plasmid expressing rat HIMF.
Lysates were prepared 2 days later and probed for HIMF protein expression. The region containing EmGFP linked to the artificial miRNA was then transferred into pAd.CMV-DEST by recombinase cloning (Invitrogen). We also prepared an Ad containing EmGFP along with a negative control shRNAmiR (Ad-EmGFP-NEG-shRNAmiR), predicted not to target any known vertebrate gene. Large-scale amplification and purification of virus was performed by Vector Biolabs (Philadelphia, PA) or in our laboratory using Adenopure LS adenovirus purification kit (Pursyn, Inc; Malvern, PA) according to the manufacturer's instructions.
HIMF/FIZZ1/RELMα in Pulmonary Hypertension 
In vivo knockdown of HIMF in the chronic hypoxia model of PH. For hypoxia studies, animals
were given either 0.5-1.0x10 9 pfu Ad-EmGFP-HIMF-shRNAmiR, or Ad-EmGFP-NEGshRNAmiR intratracheally and allowed to recover for 48 h before being placed into Plexiglass chambers for exposure to hypoxia or normoxia. The two groups of rats (Ad-EmGFP-HIMFshRNAmiR and Ad-EmGFP-NEG-shRNAmiR) were exposed to either normal room air (20.8%
Valencia, CA). A small amount of the purified total RNA (1-5 µg) resulting from these purification steps was reverse transcribed with random hexamers using a commercially available kit (First Strand Synthesis Kit, Qiagen Corp.). Real-time PCR was performed on 25 ng cDNA/sample using the iQ SYBR Green Supermix and the iCycler Real Time PCR Detection System (Bio-Rad). Annealing temperatures were optimized by gradient PCR. The fold change in expression in GFP relative to 18S rRNA was calculated based on the threshold cycle (Ct) as 2 -∆(∆Ct) , where ∆Ct = Cttarget-Ct18S and ∆(∆Ct) = ACtsample-vCtcontrol). GFP-and 18S-rRNA-specific primers were selected in silico with Beacon Designer Software (Bio-Rad, Hercules, CA). The sequences of these primers were: GFP-F, catcctggtcagactggac, GFP-R, gacttgaagaagtcgtgc; 18S rRNA-F, agttccagcacattttgcgag, 18S rRNA-R, tgctcctccgtgagttctc. All PCR products were initially separated by agarose gel electrophoresis (1%, in TAE buffer) to verify product formation and expected size. To confirm the identity of the PCR product, DNA was extracted from the band (GeneClean II, MP Biomedical, Solon, OH), cloned into a TA cloning vector (Invitrogen), and the cloned insert then sequenced.
Visualization of GFP.
The left lobe of the lung was tied off while the right lobes of the lung were perfused with cold 4% paraformaldehyde for 10 min. The right lobes were then inflated through the trachea with 4% paraformaldehyde, tied off, and immersed in 4% parafromaldehyde overnight. The next day, the lungs were washed with PBS and kept in cold (4°C) PBS for up to 2 weeks. The day before sectioning, the lungs were placed in 18% sucrose in PBS. Ten-micron sections were cut on a cryostat and then directly imaged on a Nikon Eclipse Model TE2000-S fluorescent microscope. Images were captured with a Retiga 2000R camera and imported into Image ProPlus (v.5.1). All fluorescent images were collected using an identical exposure time.
In vivo hemodynamic analysis. To obtain in vivo hemodynamic measurements, rats were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). The rats were then ventilated by the insertion of a tracheal cannula attached to a rodent ventilator (Harvard Apparatus; South Natick, MA) set to 90 breaths/min with a tidal volume of 8 ml/kg body weight.
The chest was opened with a midline incision, and then a four-electrode pressure-volume catheter (Millar Instruments, Houston, TX) was placed through the right ventricular apex to record chamber volume by impedance and pressure micromanometry as described previously (33, 42 Evaluation of vascular remodeling. Pulmonary vascular remodeling of the rats was assessed as we have previously published (8, 9, 40) . For initial analysis, sections were stained with hematoxylin and eosin. Additional lung sections were dual labeled with von Willebrand factor to stain endothelium and α-smooth muscle actin for vascular smooth muscle, as we have described (40). To examine cellular proliferation, lung sections were stained for PCNA as we have described (39) and then counterstained with hematoxylin. To assess remodeling of the lung arteries and arterioles, 100 arteries per lung section were randomly examined by an investigator blinded to treatment group using an Olympus-BHS microscope attached to a QImaging Retiga 4000RV digital camera. Small arteries with an internal diameter of <80 µm were then classified as non-muscular (NM), partially muscular (PM), or fully muscular (FM), according to α-smooth muscle actin staining. PM vessels contained at least one cell that was positive for α-smooth muscle actin but lacked a continuous layer. FM vessels had a continuous α-smooth muscle actin band. These vessels were then analyzed as described (25, 40 
Statistical analysis. Experimental values are expressed as mean ± standard error (SE). A paired
Student's t-test was used to compare the mean responses of two groups. ANOVA was used to compare the mean responses among experimental and control groups for experiments containing multiple groups. The Tukey's multiple comparison test was used to determine between which groups significant differences existed. A p value of <0.05 was considered statistically significant. Figure 1A shows that 4 days after tracheal instillation of the adenovirus Ad-EmGFP-HIMF-shRNAmiR (Ad-HIMFshRNA), engineered to suppress HIMF expression and produce GFP, the overwhelming majority of GFP was detected in the lung. A very small amount of GFP was detected in the liver, but it was <0.1% of that in the lung after normalization by 18S rRNA. No GFP was detected in the heart, spleen, or brain. In order to better evaluate the viral distribution, we collected the left lung 4 days after the intratracheal instillation of Ad-EmGFP-Neg-shRNAmiR (Ad-Neg-shRNA) and divided it into 4 equal sections. The lung sections were then processed for Western blot analysis. Equal amounts of GFP protein were seen in each section of the left lung, suggesting an even distribution of the adenoviral vector (Fig. 1B) . We also visualized the viral-induced GFP expression. Frozen lung sections from Ad-Neg-shRNA vector displayed intense GFP signal that appeared to be evenly distributed throughout the lungs (Fig. 1C) .
RESULTS
Efficiency of in vivo knockdown of HIMF in the chronic hypoxia model.
We have previously demonstrated that peak HIMF expression occurs 4 days following chronic hypoxia exposure (34) . Therefore, we compared the efficiency of HIMF suppression by the Ad-HIMF-shRNA to that resulting from a vector expressing a non-specific shRNAmiR-AdEmGFP-Neg-shRNAmiR (Ad-Neg-shRNA)-at this time point. Lungs from animals treated for 4 days with Ad-HIMF-shRNA or Ad-Neg-shRNA in either hypoxia (10% O 2 ) or normoxia (20.8%
O 2 ) were excised and processed for Western blot analysis. Immunoblotting revealed increased HIMF expression in the lungs of rats exposed to 4 days of hypoxia, but not in the lungs of normoxic animals. Introduction of Ad-HIMF-shRNA reduced hypoxia-induced HIMF expression ( Fig. 1D ), whereas the Ad-Neg-shRNA had no effect. HIMF expression in untreated normoxic/hypoxic rats was similar to that of normoxic/hypoxic animals treated with Ad-NegshRNA (data not shown).
Effect of HIMF knockdown on vascular remodeling in the chronic hypoxia model of PH. Rats
were treated with Ad-Neg-shRNA or Ad-HIMF-shRNA and exposed to normoxia or hypoxia for 14 days. Among the animals exposed to hypoxia, those pretreated with Ad-HIMF-shRNA exhibited ~45% less RV hypertrophy (0.33±0.02) than control animals exposed to Ad-NegshRNA (0.41±0.01; Fig 3C ). This increased α-smooth muscle actin staining was greatly reduced by knock down of hypoxia-induced HIMF expression (Fig. 3D ).
The %MT of pulmonary vessels was decreased in rats exposed to hypoxia+Ad-HIMFshRNA compared to rats exposed to hypoxia+Ad-Neg-shRNA (Fig. 2C) . The %MT of vessels from hypoxic rats that were 25-50 µm in external diameter decreased from 50.41±1.97%
(hypoxia+Ad-Neg-shRNA) to 26.87±1.49% (hypoxia+Ad-HIMF-shRNA) (p<0.001; Fig. 2C ). The hypoxia-induced increase in %MT also was reduced in vessels 50-100 µm in external diameter from 36.76±1.81% in hypoxia+Ad-Neg-shRNA rats to 22.61±1.34% in hypoxia+Ad-HIMFshRNA-treated animals (p<0.001; Fig. 2C ). There were no statistically significant changes in %MT of vessels 100-200 µm in external diameter, but there was a similar trend in reduction of the %MT. Histological representation of changes in %MT are shown in Figure 3E -H for vessels of approximately 50 µm in external diameter. Hypoxia led to increases in the thickness of the vessel wall and intima (Fig. 3G ), but these changes were absent in lung vessels of rats treated with Ad-HIMF-shRNA (Fig. 3H) .
Effect of HIMF knockdown on hemodynamic parameters in the chronic hypoxia model of PH.
Exposure to 14 days of hypoxia created a PH condition in the Ad-Neg-shRNA-treated rats that resulted in significantly increased mPAP, PVR, RV end systolic pressure (RVESP), and RV end diastolic pressure (RVEDP) and significantly decreased cardiac output (CO) (Fig. 4) 10 VP] is illustrated in Figure 5 . Western blot analysis revealed that HIMF expression was substantially higher in the lungs of rats that received AAV-HIMF than in those of controls ( Fig.   5B ). To localize the expression of the AAV-HIMF, we performed immunochemistry for murine HIMF on rat lungs that were intratracheally given equal concentrations of either AAV-null or AAV-HIMF (5x10 10 VP) (Fig. 5) . HIMF was undetectable in the lungs of rats that were given the AAV-null (Fig. 5C ). The antibody that was used for these immunohistochemistry experiments detects only murine HIMF and does not cross-react with rat HIMF; therefore, it only detected viral-induced HIMF. Evaluation of the AAV-HIMF-treated lungs revealed intense staining for HIMF, particularly in the large airways (Fig. 5D ). Alveolar epithelial cells as well as the vasculature stained positive for murine HIMF (Fig. 5D) . Figure 5E shows a detailed view of an airway and vessel that stained positive for murine HIMF. It is possible, but not likely, that the introduction of AAV into the lungs can induce pulmonary inflammation (2, 43) . We therefore examined the AAV-null slides for an inflammatory response. There was no noticeable pulmonary inflammation associated with the introduction of AAV-null when compared to simultaneously prepared vehicle controls (data not shown).
Effect of pulmonary HIMF gene transfer on vascular remodeling. Thirty-five days after rats were instilled with AAV-HIMF, the RV/LV+S ratio was ~32% greater than that in both vehicle-treated and AAV-null controls (p<0.01; Fig. 6A ). The muscularization of small pulmonary vessels was also markedly increased (Fig. 6C, F) . Layering of smooth muscle cells within the intima of blood vessels from the lungs of rats treated with AAV-HIMF was substantially increased compared to that in similarly sized vessels from control animals (Fig. 6B, C Fig. 6G ). The %MT also was increased in vessels 50-100 µm in external diameter from 19.77±1.05% in vehicle and 15.02±0.85% in AAV-null control rats to 29.59±1.50% in AAV-HIMF-treated animals (p<0.001; Fig. 6G ). There were no significant changes in %MT of vessels 100-200 µm in external diameter, but there was a trend toward increased %MT (Fig. 6G ).
To determine if cellular proliferation was occurring in the vasculature of rats treated with AAV-HIMF, we performed immunohistochemistry for the cell proliferation marker PCNA (Fig. 6D,   E ). Pulmonary vessels from rats treated with AAV-HIMF for 14 days displayed an increased number of PCNA-positive cells. These cells were particularly prominent in the smooth muscle layer (Fig. 6E, arrows) as well as in the endothelial cell layer (Fig. 6E, arrowheads) . Vessels from control animals did not display PCNA-positive cells in either of these layers (Fig. 6D) .
Analysis of right heart hypertrophy as determined by the RV/(LV+S) ratio 14 days after AAV-HIMF treatment revealed no significant changes (data not shown); however, mild but significant changes in vascular muscularization were noted (Fig. 6F) (Fig. 6F ). There were no differences in the %MT of vessels with external diameters of 25-50 µm between the experimental and vehicle control group, but there was a significant difference between AAV-HIMF (27.68±2.16%) and AAV-null (19.44±0.77%; p<0.01) (Fig. 6G) . The %MT of vessels 50-100 µm in external diameter was significantly greater in AAV-HIMF-treated rats (24.86±1.35%) than in either vehicle-treated (19.85±0.89%; p<0.01) or AAV-null-treated (16.59±0.91%; p<0.001) control animals (Fig. 6G) .
The %MT in 100-200 µm vessels also was greater in AAV-HIMF-treated animals (20.28±1.84%) than in controls (vehicle: 11.00±1.57%; p<0.01; AAV-null: 9.59±1.22%; p<0.01).
Rats examined 7 days after treatment with AAV-HIMF displayed no changes in RV hypertrophy, muscularization, or %MT of the pulmonary arteries (data not shown). Woods Units in AAV-HIMF-treated animals (p<0.01; Fig. 7B ). In addition, the RVESP was significantly higher in the AAV-HIMF-treated rats (34.00±0.71 mmHg) than in the control rats (24±1.92 mmHg; p<0.05; Fig. 7C ). There were no differences between the two groups in RVEDP (Fig. 7D) , CO (Fig. 7E ), or LVEDP (Fig. 7F) . As an additional control, we evaluated 
In vivo hemodynamics after
DISCUSSION
There has been much discussion, speculation, and indirect evidence regarding the involvement of HIMF in pulmonary vascular remodeling and PH, but this report is the first to provide definitive proof that HIMF is directly involved. We initially focused our research on HIMF because of its prominence in the chronic hypoxia model of PH as shown through microarray analysis (34) . We found that HIMF has biological properties that make it an intriguing candidate for pathologic signaling in the development of PH. These include its co-localization in PCNA-positive Neo-muscularization of small, previously non-muscular arterioles and hyperplasia and hypertrophy of vascular smooth muscle in these and larger muscular pulmonary arterioles and arteries are hallmarks of PH (4, 28) . Medial thickening and neointima formation require a dysregulation of cellular proliferation, particularly of vascular smooth muscle. Here, we showed that HIMF can induce medial thickening as well as vascular smooth muscle proliferation through pulmonary HIMF gene transfer (Fig. 6 ). We also showed that knocking down HIMF protein expression in the chronic hypoxia model of PH reduces these effects (Fig. 2) . Our laboratory has demonstrated that HIMF is expressed in and co-localizes with PCNA in developing murine lung, particular in the saccular and alveolar stages during times of intense cell proliferation (39).
In the current study, vessels from rats that were intratracheally treated with AAV-HIMF displayed increased PCNA-positive staining in the smooth muscle layer (Fig. 6E) . Li et al. (16) also has demonstrated that HIMF is intensely expressed in the lung during compensatory growth following pneumonectomy in the same cells and is temporally coincident with the cell proliferation marker PCNA. It is interesting to note that a recent study established that HIMF is expressed in the remodeling pulmonary arteries of mice with antigen-induced asthma (6). As stated above, we have previously published that the addition of recombinant murine HIMF to cultured rat pulmonary microvascular smooth muscle cells increases the proliferative response in a dose-dependent manner (34) . Taken together, these data suggest that HIMF induces direct cellular proliferation that could mediate the vascular remodeling of PH, consistent with our current observations that HIMF induces lung vascular remodeling identical to that which occurs following chronic hypoxia. 
